Table S2 from PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
收藏NIAID Data Ecosystem2026-05-17 收录
数据链接：
官方服务：
资源简介：
PQR309 activity, combinations of PQR309 with additional drugs, BCL2, MYC and TP53 status in lymphoma cell lines.
创建时间：
2018-01-01
